Publications by authors named "K Benabdellah"

The CRISPR gene editing tool holds great potential for curing genetic disorders. However, the safe, efficient, and specific delivery of the CRISPR/Cas9 components into cells and tissues remains a challenge. While many currently available delivery methods achieve high levels of gene editing effects in vivo, they often result in genotoxicity and immunogenicity.

View Article and Find Full Text PDF

Introduction: Chimeric antigen receptor-expressing T cells (CAR T cells) have revolutionized cancer treatment, particularly in B cell malignancies. However, the use of autologous T cells for CAR T therapy presents several limitations, including high costs, variable efficacy, and adverse effects linked to cell phenotype.

Methods: To overcome these challenges, we developed a strategy to generate universal and safe anti-CD19 CAR T cells with a defined memory phenotype.

View Article and Find Full Text PDF

Background: Active targeting by surface-modified nanoplatforms enables a more precise and elevated accumulation of nanoparticles within the tumor, thereby enhancing drug delivery and efficacy for a successful cancer treatment. However, surface functionalization involves complex procedures that increase costs and timelines, presenting challenges for clinical implementation. Biomimetic nanoparticles (BNPs) have emerged as unique drug delivery platforms that overcome the limitations of actively targeted nanoparticles.

View Article and Find Full Text PDF

The 14th African Society of Human Genetics (AfSHG) Morocco Meeting and 2nd International Congress of the Moroccan Society of Genomics and Human Genetics (SM2GH), held in Rabat, Morocco, from December 12 through 17, 2022, brought together 298 attendees from 23 countries, organized by the AfSHG in collaboration with the SM2GH. The conference's overarching theme was "Applications of Genomics Medicine in Africa," covering a wide range of topics, including population genetics, genetics of infectious diseases, hereditary disorders, cancer genetics, and translational genetics. The conference aimed to address the lag in the field of genetics in Africa and highlight the potential for genetic research and personalized medicine on the continent.

View Article and Find Full Text PDF
Article Synopsis
  • - COST (European Cooperation in Science and Technology) funds and coordinates scientific research in Europe, recently supporting the "Genome Editing to treat Human Diseases" (GenE-HumDi) network that connects various stakeholders including pharmaceutical companies and academia.
  • - GenE-HumDi’s main goal is to fast-track the use of genome editing for treating human diseases through organized working groups that improve technologies, assess safety, and create regulatory guidelines.
  • - The initiative aims to standardize practices, share knowledge, and effectively communicate the potential of genome editing to the public, highlighted by their first meeting in March 2023 in Granada, Spain.
View Article and Find Full Text PDF